Approval · Notice of Compliance 12743 · 2011
PROVERA: Notice of Compliance 12743
Issued October 28, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12743
- Date
- October 28, 2011
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Alternate Manufacturing Site for the Drug Substance and Drug Product
- Therapeutic class
- Progestin
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PROVERA | Not yet assigned | — |
| PROVERA PAK | Not yet assigned | — |
Medicinal ingredients
- MEDROXYPROGESTERONE ACETATE 2.5 MG per TAB
- MEDROXYPROGESTERONE ACETATE 5 MG per TAB
- MEDROXYPROGESTERONE ACETATE 10 MG per TAB